Leerink Partners maintains Replimune Group at Outperform, raises price target to $31 from $19
Leerink Partners kept Replimune Group at Outperform, raising its price target to $31 from $19, a 63.2% increase. The new target implies a 93.0% upside from the Oct 28 close of $16.06.
How this was made

The 30-second read
Why it matters
Analyst rating changes can move thinly‑traded stocks, especially in biotech.
Market read
The upgrade may prompt short‑term buying pressure on RPLM.
What to watch
No new clinical data were released; the upgrade relies on expectations rather than concrete results.
Background
Replimune Group is a clinical‑stage biotech focused on oncolytic virus therapies.
Market effects
May lift sentiment in the biotech sector as analysts reassess small‑cap immunotherapy stocks.
Limited to U.S. markets where the stock trades.
Minimal global impact.
Counterpoint
The price target increase could be overly optimistic if upcoming trial data disappoint.
Key entities
- analystLeerink Partners
Equity research firm that issued the rating upgrade.

